HN
Hansa Biopharma AB
HNSBF · OTC
$3.70 +0.00% (+$0.00)
Market Cap 3.63B kr
P/E Ratio -
Div. Yield -
ROE -
Piotroski F-Score Weak
2/9Valuation
0 /100
Expensive P/S 19.19x
EV/EBITDA N/A
P/B N/A
Growth
79 /100
Growing Rev. growth 12.88%
FCF growth N/A
Book val. growth N/A
Profitability
20 /100
Weak Net margin 406.19%
Op. margin 310.69%
FCF margin 288.18%
Quality
3 /100
Poor ROA 71.74%
Asset turnover 0.18x
ROIC 71.73%
Debt
23 /100
High Int. coverage -3.06x
Current ratio 1.25x
Net debt/EBITDA N/A
Stability
39 /100
Moderate Rev. volatility 24.25%
EPS volatility 32.73%
Profitable years 0
Bulios Scoring descrie calitatea și istoricul unei companii, nu randamentul viitor. Un scor ridicat nu este un semnal de cumpărare. Află mai multe
Întreabă StockBot despre HNSBF
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Renée Julie Elisabet Aguiar-Lucander
Employees
125
Headquarters
Lund
Evenimente viitoare
05 NOV.
Earnings
Upcoming earnings report